PKU and a 23andMe PAH Carrier Result: What One Variant Really Means

PKU and a 23andMe PAH Carrier Result: What One Variant Really Means

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

Bottom line: Decades of population and clinical evidence show that phenylketonuria (PKU) is a recessive single-gene disorder. It appears only when a child inherits two altered copies of the PAH gene. Carrying one variant, as a 23andMe report may flag, makes you a healthy carrier, not a patient. Research behind universal newborn screening also shows that early-detected PKU is highly manageable.

What you’ll learn

• Why one PAH variant makes you a carrier, not a person with PKU.
• The exact recurrence-risk numbers if your partner is also a carrier.
• How US and Canada newborn screening, diagnosis, and testing actually work.
• What today’s PKU treatments include, up to the 2025 FDA approval of sepiapterin.

How PKU Is Inherited: The PAH Gene and Autosomal Recessive Transmission

Phenylketonuria is caused by changes in a single gene called PAH, located on chromosome 12. This gene carries the recipe for an enzyme, phenylalanine hydroxylase. Think of that enzyme as a small kitchen appliance that breaks down phenylalanine, an amino acid found in protein foods. When the appliance works, it converts phenylalanine into another amino acid, tyrosine. When it does not work, phenylalanine has nowhere to go, and levels in the blood climb. That one simple job, done or not done, sits at the center of everything else in this article.

PKU follows autosomal recessive inheritance. That phrase means a person needs two altered copies of the gene, one from each parent, before the disorder appears. Everyone carries two copies of the PAH gene. A carrier has one working copy and one non-working copy. The single working copy makes enough enzyme, so a carrier stays healthy and shows no symptoms. Picture a two-burner stove where only one burner lights: it still cooks the meal, just with a little less capacity to spare.

An affected child is different. That child inherits one non-working copy from the mother and one non-working copy from the father. With no working copy, phenylalanine builds up. Untreated, that buildup reaches toxic levels and can cause intellectual disability, seizures, and behavioral problems. The harm is not because phenylalanine is a poison in normal amounts. It is a routine part of protein. The harm comes from the body being unable to clear the excess, so ordinary meals slowly turn into a hidden overload. This is why early detection matters so much, a point later sections cover in full.

The genetics also explain why PKU comes in different strengths. Researchers cataloging the PAH gene have reported more than 1,000 distinct variants. Different variants leave different amounts of working enzyme. That range produces a spectrum of severity:

• Classic PKU — very little or no working enzyme, the highest phenylalanine levels, and the greatest risk of harm if untreated.
• Milder hyperphenylalaninemia — more residual enzyme activity, lower phenylalanine levels, and a gentler course.
• BH4-responsive forms — certain variants leave an enzyme that works better when helped by the cofactor BH4, which matters for treatment choice later.

Because two altered copies are involved, the exact pair of variants a person carries shapes where they land on that spectrum. This is why two people who both “have PKU” can need quite different care plans, and why a metabolic clinic looks at the specific genotype rather than the label alone.

One practical caution applies to consumer reports. A 23andMe carrier report typically tests only a limited panel of the most common PAH variants. So a negative report does not fully rule out carrier status. If your family history or a clinician’s concern points toward PKU, a broader clinical test is the right tool, not a consumer panel. A genetic counselor can explain which test fits your situation, and you should not treat a consumer panel as the last word on your genetics.

Section recap: PKU comes from two altered copies of the PAH gene, so a single-variant carrier stays healthy. Over 1,000 known variants explain the classic-to-mild severity range.

Risk Magnitude: Carrier Math, Absolute Recurrence Risk, and Penetrance

Genetics can feel abstract, so it helps to turn the odds into plain counts. The key rule comes from recessive inheritance. If both reproductive partners are PAH carriers, each pregnancy carries fixed probabilities. There is a 25% chance the child inherits two altered copies and is affected. There is a 50% chance the child is a carrier like the parents. There is a 25% chance the child inherits two working copies and is neither.

Translated to counts, imagine 100 pregnancies between two carrier parents. On average, the outcomes break down like this:

• About 25 out of 100 children would have PKU (two altered copies).
• About 50 out of 100 would be healthy carriers (one altered copy), just like their parents.
• About 25 out of 100 would carry no variant at all (two working copies).

These are averages across many pregnancies, not a schedule. A common misread is to assume that once a carrier couple has one affected child, the “next three are safe.” That is not how it works. Each individual pregnancy still faces the same independent 1-in-4 chance of an affected child, the same way each coin flip stays 50-50 no matter what came before.

Now consider a single carrier, like a reader who saw one PAH flag on a 23andMe report. Being a carrier means your own risk of having PKU is essentially zero, because you have a working copy. Recurrence risk only becomes relevant if your reproductive partner is also a PAH carrier. In other words, your result is a piece of family-planning information, not a personal diagnosis. It tells you something you might act on before a pregnancy, not something you need to treat in yourself.

How common is PKU in the first place? In the United States, studies report that PKU affects roughly 1 in 10,000 to 15,000 newborns. Frequency runs higher in some ancestral backgrounds:

• Higher-than-average carrier frequency is reported in people of Irish, northern European, Turkish, or Native American ancestry.
• Because carriers are far more common than affected people, most carrier couples never realize they share the trait until testing reveals it.

These are population averages, and a genetic counselor can refine risk for your specific background rather than a broad category.

PKU also behaves differently from many gene results people worry about. Untreated classic PKU has near-complete penetrance for cognitive harm, meaning the harm reliably follows without treatment. Penetrance is simply how often a gene result actually produces its effect. Many consumer-test findings carry low, fuzzy penetrance, a mere “increased risk.” Untreated PKU is the opposite: the outcome is close to certain without care, which is exactly why every baby is screened at birth, as the next section explains. A metabolic clinician or counselor can put your own numbers in context.

Section recap: For two carrier parents, each pregnancy has a 25% chance of an affected child, so about 25 of 100. A single carrier faces near-zero personal risk, with recurrence risk only through a carrier partner.

Testing Options: Newborn Screening, Diagnostic Confirmation, and DTC Reports

A US or Canada reader meets PKU testing in several very different settings, and sorting them out prevents needless worry. They are not interchangeable: one finds affected babies, one confirms a diagnosis, one flags carriers, and one is planned ahead of a pregnancy. The table below lays them side by side.

Testing setting	Who it is for	What it checks	Diagnostic?
Universal newborn screening	Every newborn	Blood phenylalanine level via heel-prick in the first days of life	No — a flag that triggers confirmation
Diagnostic confirmation	Babies (or people) with an abnormal screen	Plasma amino-acid quantitation + PAH gene sequencing in a CLIA-certified lab	Yes — this is what confirms PKU
Direct-to-consumer / clinical panel	Adults curious about carrier status	A limited set of specific PAH variants (23andMe; or panels via Invitae, Color, Labcorp, Quest)	No — screens limited variants only
Carrier screening before/during pregnancy	Couples planning a family	Whether each partner carries a PAH variant	No — reproductive planning information

The first setting is universal newborn screening. Every US state and every Canadian province screens newborn blood for phenylalanine, usually through a heel-prick sample in the first days of life. This program is old and proven; broad screening began in 1963, when Massachusetts became the first state to require it. In the US, PKU sits on the federal Recommended Uniform Screening Panel that guides state programs. This is why nearly every parent has a hazy memory of a nurse pricking a newborn’s heel, even if they never knew the test’s name.

The second setting is diagnostic confirmation. When a newborn screen shows elevated phenylalanine, it is a flag, not a final answer. Clinicians confirm PKU with plasma amino-acid quantitation and PAH gene sequencing performed in CLIA-certified laboratories. Only then does a diagnosis become firm, and treatment can begin within days. Think of the screen as a smoke alarm and the confirmatory test as the fire inspector who checks what actually happened. A smoke alarm that sounds does not mean the house is burning; it means someone should look.

The third setting is direct-to-consumer and clinical panel testing. Consumer reports such as the 23andMe carrier-status product, and clinician-ordered panels from labs like Invitae, Color, Labcorp, or Quest, test for specific variants. Consumer reports in particular check only a limited set and are not diagnostic. A positive consumer flag is a reason to ask questions, not a diagnosis of anything. Treating a single carrier line as a verdict is like reading one page of a report and assuming you know the ending.

For adults planning a family, a fourth option exists: carrier screening before or during pregnancy. Professional bodies, including the American College of Obstetricians and Gynecologists and the American College of Medical Genetics and Genomics, support offering expanded carrier screening to couples. Your obstetrician, primary care physician, or a genetic counselor can arrange it. You can find a board-certified counselor through the National Society of Genetic Counselors at NSGC.org.

Section recap: Newborn screening catches affected babies within days, clinical labs confirm diagnoses, and consumer panels only flag limited variants. Carrier screening before pregnancy is a separate, planned option.

Interpreting Your Result: Diagnostic vs Carrier vs Variant of Uncertain Significance

Test results come in categories, and mixing them up is the main source of panic. A diagnosis of PKU requires two things together: two pathogenic PAH variants and elevated phenylalanine confirmed clinically. That combination, not a single line on a report, defines the condition. A carrier finding is different. It means one pathogenic variant in an unaffected person, and its meaning is reproductive, not personal. Keeping these three buckets straight removes most of the fear:

• Diagnosis (PKU) — two pathogenic PAH variants plus clinically confirmed high phenylalanine. This is the actual condition.
• Carrier — one pathogenic PAH variant in a healthy person. Relevant to future children, not to your own health.
• Variant of uncertain significance (VUS) — a change the lab cannot yet call harmful or harmless. It is a “not enough evidence yet” label, not bad news.

That third category confuses many readers. Professional standards from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology set the rules for classifying variants. They sort variants into five tiers:

Classification	Plain meaning
Pathogenic	Known to cause the condition
Likely pathogenic	Strong evidence it is harmful, not yet certain
Uncertain (VUS)	Not enough evidence to call either way
Likely benign	Strong evidence it is harmless
Benign	Known to be harmless

A useful analogy is a weather forecast. “Pathogenic” is like a confirmed storm warning, “benign” is a clear day, and a VUS is a forecast the meteorologists are still debating. You would not evacuate on a debated forecast, and you should not assume the worst from a VUS. Labs report the tier precisely so you and your clinician can judge how solid the finding is, and a VUS may be reclassified later as more data arrive.

For a reader with a single carrier result on a consumer panel, the reassuring reading is straightforward. One pathogenic PAH variant means you are healthy and simply a carrier. The actionable next step is understanding your partner’s carrier status, not tracking personal disease risk. If any consumer result concerns you, confirm it through a clinical genetics evaluation rather than acting on the raw report. A genetic counselor can order and interpret that confirmation, and can tell you whether a finding even warrants follow-up.

Section recap: A diagnosis needs two pathogenic variants plus elevated phenylalanine; one variant is a healthy carrier finding. A VUS is unclassified and may be reclassified, so confirm concerning consumer results clinically.

Prevention and Lifelong Management: The Low-Phenylalanine Diet and Early Detection

PKU cannot be prevented at the level of the gene, because the gene change is inherited. What research has demonstrated is that harm is highly preventable through early detection plus lifelong control of phenylalanine. That is the core reason newborn screening exists. Caught in the first days of life and managed from the start, an affected child can develop normally. The disability that older textbooks describe is largely a picture of the pre-screening era, not of a child treated from birth today.

The foundation of management is a low-phenylalanine diet paired with a special medical formula. The formula supplies the protein building blocks the body needs while limiting phenylalanine. Nutrition-management guidelines from Genetic Metabolic Dietitians International and partner networks detail how metabolic dietitians select medical foods and monitor for nutrient gaps. In practice, the daily routine involves several moving parts:

• A tightly measured low-protein diet, since phenylalanine rides along with dietary protein.
• A phenylalanine-free medical formula, which delivers safe protein building blocks and key nutrients.
• Regular blood-phenylalanine monitoring, so intake can be adjusted before levels drift too high or too low.
• Ongoing dietitian oversight, to prevent the nutrient gaps a restricted diet can cause.

This is skilled, ongoing work, not a simple grocery swap, which is why a metabolic dietitian is central to care. Guidelines set concrete targets. The 2014 ACMG guideline recommends keeping blood phenylalanine in the 120 to 360 micromoles-per-liter range as the main therapeutic goal. The 2023 evidence-based ACMG guideline, published in December 2024, reaffirms lifelong treatment for people with untreated levels above 360 micromoles per liter, the “diet for life” approach. Current guidance favors staying on management for life rather than stopping in adolescence, a shift from older practice that once let some teenagers loosen the diet.

One situation deserves special emphasis: maternal PKU. When a woman who has PKU becomes pregnant, uncontrolled phenylalanine crosses the placenta and harms the developing fetus. Research reports that without dietary control, over 90% of such pregnancies face serious effects, including microcephaly, growth restriction, intellectual disability, and heart defects. Crucially, the baby usually does not have PKU; the harm comes from the mother’s high phenylalanine flooding the fetus, so the fix is controlling the mother’s levels, not the baby’s genes. Tight control before conception and throughout pregnancy is the established prevention. This matters even for a carrier reader, because a carrier’s relative might have PKU.

To be clear for a carrier reader: carriers themselves do not follow the PKU diet, because a carrier is healthy. The diet and strict monitoring apply to people who have PKU, and to mothers who have PKU during pregnancy. If you are only a carrier, nothing about your own eating needs to change. Any personal management plan should be set by a metabolic clinician, not a website.

Section recap: PKU harm is prevented by early detection plus a lifelong low-phenylalanine diet with medical formula, guided by targets of 120 to 360 micromoles per liter. Maternal PKU requires especially tight control during pregnancy.

The 2025 Treatment Landscape: Sapropterin, Pegvaliase, and Sephience (Sepiapterin)

Medicines now supplement, but do not replace, the diet. Three drugs are FDA-approved, and they work in different ways for different patients. The table below summarizes them before the detail follows.

Drug (brand)	Mechanism	Who it is for	FDA approval date
Sapropterin (Kuvan)	Synthetic BH4 cofactor that boosts residual enzyme activity	People with BH4-responsive PKU	December 13, 2007
Pegvaliase (Palynziq)	Enzyme injection that breaks down phenylalanine directly	Adults with uncontrolled blood Phe (>600 µmol/L) on existing care	May 24, 2018
Sepiapterin (Sephience)	PAH activator and natural BH4 precursor that lowers blood Phe	Adults and children ≥ 1 month with sepiapterin-responsive PKU/HPA	July 28, 2025

The oldest option is sapropterin dihydrochloride, sold as Kuvan. The FDA approved it on December 13, 2007 as a synthetic form of the cofactor BH4, for people whose PKU responds to BH4. It was the first specific drug therapy for PKU. Think of BH4 as a helper that props up a partly working enzyme; if a person’s specific variants leave some enzyme to prop up, the drug can help. Responsiveness varies with the exact PAH variants, which is why not everyone benefits.

The next option is pegvaliase, sold as Palynziq. The FDA approved it on May 24, 2018 for adults with uncontrolled blood phenylalanine, defined as above 600 micromoles per liter on existing management. It is an injection that works differently, using an enzyme to convert phenylalanine into other substances the body can handle. Rather than propping up the person’s own enzyme, it brings in an outside one to do the job. Because it is a stronger and different approach, it is reserved for adults who need it and is supervised closely by a specialist.

The newest option is sepiapterin, sold as Sephience. The FDA approved it on July 28, 2025, for hyperphenylalaninemia in adults and children aged 1 month and older with sepiapterin-responsive PKU. Sepiapterin is a phenylalanine hydroxylase activator and a natural precursor of BH4, and it works to lower blood phenylalanine. A phase 3 trial extension studied how far patients could ease their diet. Research reported that over 97% of participants on that protocol could liberalize their diet, with mean protein intake rising by 126%. For families who have measured every gram of protein for years, that is a meaningful shift, though it is not a cure and the diet does not vanish.

Regulators and jurisdictions differ, so timing matters. The dates above are FDA approvals; Health Canada’s review status for sepiapterin may differ from the FDA and can change over time. A reader in Canada should not assume a US approval date equals local availability. Ask a metabolic clinic about current access where you live, since coverage and timing move faster than any article can track.

The single most important caveat is individualization. For every one of these drugs, eligibility depends on demonstrated responsiveness and specialist evaluation, and each supplements rather than replaces dietary management. None of this is a self-service choice. Only a metabolic clinician can decide whether a person qualifies, and a genetic counselor can help a family understand the options.

Section recap: Sapropterin (FDA 2007), pegvaliase (FDA 2018), and sepiapterin/Sephience (FDA July 28, 2025) all supplement the diet, and each requires proven responsiveness and specialist supervision. Health Canada status can differ from the FDA.

Family Implications: Partner Testing and Cascade Carrier Screening

Because PKU is recessive, one carrier result ripples through a family in a predictable way. Clinicians call the follow-up process cascade testing: checking relatives once a variant is known. Each full sibling of a carrier has a 50% chance of also being a carrier, since siblings share parents. That figure is a starting point for deciding who might want testing, not a cause for alarm.

For a reader thinking about future children, the most actionable step is clear: learn your reproductive partner’s PAH carrier status. The two possible outcomes lead to very different paths:

• Partner is not a carrier — your children cannot inherit two variants from the two of you, so they cannot have PKU from this pairing.
• Partner is also a carrier — the 25% per-pregnancy figure from earlier applies, and further planning options open up.

That single test result is the pivot point for everything that follows, which is why counselors treat partner testing as the first practical move rather than testing every relative at once.

US and Canada couples have several evidence-supported paths. Expanded carrier screening before pregnancy can identify carrier couples early. For couples known to both carry a PAH variant, more options open up, including:

• Prenatal diagnosis during a pregnancy, to learn whether the fetus is affected.
• Preimplantation genetic testing for monogenic conditions (PGT-M), used with in vitro fertilization to select unaffected embryos.
• Expanded carrier screening for the couple before conception, so choices are made with full information.

Professional carrier-screening statements from ACOG and ACMG frame these choices. A simple analogy helps: think of cascade testing like tracing a shared family recipe. Once you know one relative has a particular ingredient, it is worth asking who else might. A board-certified genetic counselor can map which relatives could benefit from testing and in what order, without pressure. You can find one through the National Society of Genetic Counselors at NSGC.org. This mapping is medical guidance, so a counselor or clinician should lead it rather than a search result.

Section recap: Each sibling of a carrier has a 50% chance of also carrying a variant, so partner testing is the key next step. Carrier couples can consider expanded screening, prenatal diagnosis, and PGT-M with counselor guidance.

Psychosocial and Legal Context: GINA, Insurance Gaps, and Disclosure to Relatives

Worry about insurance and about telling relatives is common and reasonable. US law offers real, but partial, protection. The Genetic Information Nondiscrimination Act of 2008, known as GINA, bars health insurers and employers from using genetic information in coverage, premium, or employment decisions. The Affordable Care Act adds a further bar against health-plan discrimination for pre-existing conditions. Together these cover the two areas most people ask about first. But the coverage has a clear edge, and knowing where it stops is the whole point:

Protected by US GINA	Not protected by US GINA
Health insurance (coverage and premiums)	Life insurance
Employment decisions	Disability insurance
(Plus ACA bar on pre-existing-condition discrimination)	Long-term-care insurance

The gap is important to know before you apply for anything. GINA does not cover life insurance, disability insurance, or long-term-care insurance. Insurers in those categories may use genetic and family-health information for their decisions unless a stronger state law applies. So a reader weighing a life-insurance application may want to understand this gap, and possibly speak with a counselor, before testing or disclosing. Buying that kind of coverage before testing is a choice some people make for exactly this reason. This is educational context, not legal advice.

Canada’s framework is broader. The Genetic Non-Discrimination Act became law on May 4, 2017. It prohibits requiring or using genetic-test results as a condition of providing goods, services, or contracts, and that includes insurance. On July 10, 2020, the Supreme Court of Canada upheld the Act as constitutional, holding that genetic privacy is part of core personal information deserving protection. A Canadian reader therefore has stronger statutory footing than a US reader. The practical upshot is worth stating plainly:

• In the US, life, disability, and long-term-care insurers may consider genetic information unless a stronger state law applies.
• In Canada, the 2017 Act blocks using genetic-test results as a condition of goods, services, or contracts, including insurance.

Disclosure to relatives has an emotional side too. Telling siblings that you carry a PAH variant can feel awkward, yet it gives them useful reproductive information, since each has a 50% chance of also carrying it. Framing the conversation as a helpful heads-up, rather than bad news, often lands better. Many people find it easier to share the recurrence math than the label, since “here is a number that might matter for your family planning” feels less like an accusation and more like a gift. A board-certified genetic counselor can help you plan what to say and to whom, and can navigate the insurance and disclosure questions with you. For anything legal, consult a qualified professional, and for care decisions, consult a clinician.

Section recap: US GINA protects health coverage and employment but not life, disability, or long-term-care insurance; Canada’s 2017 law is broader. A genetic counselor can help with both disclosure and the insurance gap.

Frequently Asked Questions

Will I get PKU if my 23andMe report flags one PAH variant? No. A single PAH variant makes you a healthy, unaffected carrier, because your other copy of the gene still works. PKU requires two pathogenic copies plus elevated phenylalanine confirmed clinically. If the result concerns you, a genetic counselor can confirm and explain it.

Will my children inherit PKU because I am a carrier? Only if your reproductive partner is also a PAH carrier. In that case, each pregnancy carries a 25% chance of an affected child, so about 25 out of 100. Partner carrier testing is the key next step, and a counselor can arrange it.

Will this affect my health or life insurance? In the US, GINA protects health insurance and employment but not life, disability, or long-term-care insurance. In Canada, the 2017 Genetic Non-Discrimination Act offers broader protection, upheld by the Supreme Court in 2020. Understand the gap before you apply.

Can my employer find out about my genetic result? In the US, GINA prohibits employers from using genetic information in employment decisions. Canada’s 2017 law also bars using genetic-test results as a condition of services and contracts. A genetic counselor can help you think through disclosure choices.

Should I get a second opinion or clinical confirmation of a consumer result? Yes, if a consumer result concerns you. Direct-to-consumer panels test only limited variants and are not diagnostic. Confirm any worrying result through a CLIA-certified clinical genetics evaluation, arranged by a clinician or genetic counselor.

Summary

The research is consistent and reassuring for a worried carrier. PKU is an autosomal recessive disorder of the single PAH gene, so a person needs two altered copies to be affected. Carrying one variant, as a 23andMe report may flag, makes you a healthy carrier, and your own risk of the condition is essentially zero. Recurrence risk only enters the picture if your reproductive partner is also a carrier, in which case each pregnancy has a 25% chance of an affected child. Everything else in your plan flows from that one partner-status question.

The practical path is clear. Newborn screening in every US state and Canadian province detects affected babies within days, and early, lifelong phenylalanine control lets those children develop normally. Treatments now include sapropterin (FDA 2007), pegvaliase (FDA 2018), and sepiapterin/Sephience (FDA July 28, 2025), each supplementing the diet for eligible, responsive patients. For your family, the most useful next steps are partner testing and a conversation with a board-certified genetic counselor at NSGC.org. It also helps to know the legal picture: in the US, GINA protects health coverage but not life insurance, while Canada’s law is broader.

This article is for educational purposes only. It is not a substitute for advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. For any decisions about testing, treatment, or care, consult a qualified clinician. In emergencies, call 911.

References

1. NIH / MedlinePlus Genetics (2024). Phenylketonuria — MedlinePlus Genetics. National Library of Medicine. https://medlineplus.gov/genetics/condition/phenylketonuria/
2. CDC (2024). Newborn Screening for Phenylketonuria (PKU) and Maternal PKU. Centers for Disease Control and Prevention. https://www.cdc.gov/newborn-screening/about/phenylketonuria.html
3. FDA (2025). FDA Approval of Sephience (sepiapterin) for Phenylketonuria. U.S. Food and Drug Administration. https://www.fda.gov/drugs/news-events-human-drugs
4. Smith et al. (2024). Phenylalanine hydroxylase deficiency diagnosis and management: A 2023 evidence-based clinical guideline of the ACMG. Genetics in Medicine. https://pubmed.ncbi.nlm.nih.gov/39630157/
5. Vockley et al. (2014). Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genetics in Medicine, 16(2):188-200. https://pubmed.ncbi.nlm.nih.gov/24385074/
6. OMIM #261600 (2024). Phenylketonuria; PKU — OMIM Entry #261600. Johns Hopkins University. https://omim.org/entry/261600
7. FDA / BioMarin (2007, 2018). Sapropterin (Kuvan) and Pegvaliase (Palynziq) FDA approvals for PKU. https://www.accessdata.fda.gov/scripts/cder/daf/
8. GeneReviews (NCBI Bookshelf). Phenylalanine Hydroxylase Deficiency — GeneReviews (NBK1504). University of Washington. https://www.ncbi.nlm.nih.gov/books/NBK1504/
9. Singh et al. (2014). Recommendations for the nutrition management of phenylalanine hydroxylase deficiency. Genetics in Medicine, 16:121-131. https://pubmed.ncbi.nlm.nih.gov/24385075/
10. Richards et al. (2015). Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the ACMG and AMP. Genetics in Medicine, 17:405-424. https://pmc.ncbi.nlm.nih.gov/articles/PMC4544753/
11. NHGRI / genome.gov (2024). Genetic Discrimination and the Genetic Information Nondiscrimination Act (GINA). National Human Genome Research Institute. https://www.genome.gov/about-genomics/policy-issues/Genetic-Discrimination
12. Supreme Court of Canada / Justice Laws (2017, 2020). Genetic Non-Discrimination Act (SC 2017, c.3) and Reference re Genetic Non-Discrimination Act (2020 SCC 17). https://laws-lois.justice.gc.ca/eng/annualstatutes/2017_3/page-1.html
13. NORD (2024). Phenylketonuria — NORD Rare Disease Database. National Organization for Rare Disorders. https://rarediseases.org/rare-diseases/phenylketonuria/

Last updated: 2026-07-25

Author: genelumen editorial team. This article aggregates 13 sources from peer-reviewed medical literature and public health agencies (tier 1=8 / tier 2=5), including NIH, CDC, Health Canada, ACMG guidelines, and PubMed-indexed publications.

This article is for educational purposes only and is not a substitute for medical advice from a licensed physician, board-certified medical geneticist, or board-certified genetic counselor. In emergencies, call 911 (US/Canada) or 119 (Japan).

Related: Genetic Diseases category

🇯🇵 For readers in Japan — a separate Japanese edition written for Japan’s healthcare system (not a translation): https://genelumen.com/ja/ja-metabolic-hematologic-genetic/phenylketonuria-carrier-inheritance-japan-guide